Clinical analysis of patients (pts) with Lung cancer treated with anti-PD1/PDL1 therapy.

被引：0
|
作者：
Tian, Kaihua
Wang, Xintong
机构：
[1] Qingdao Univ, Affiliated Hosp, Qingdao, Peoples R China
[2] ChosenMed Technol Co Ltd, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
20522
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis
    Jiang, Qi
    Huang, Jinsheng
    Zhang, Bei
    Li, Xujia
    Chen, Xiuxing
    Cui, Bokang
    Li, Shengping
    Guo, Guifang
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [22] Efficacy of anti-PD1/PDL1 antibody monotherapy in patients with advanced non-small cell lung cancer with increased hepcidin expression
    Yamamoto, M.
    Hirama, N.
    Teranishi, S.
    Tashiro, K.
    Kubo, S.
    Kudo, M.
    Kaneko, T.
    [J]. ANNALS OF ONCOLOGY, 2023, 34
  • [23] Off treatment survival (OTS) in patients (pts) with advanced melanoma after anti-PD1 therapy.
    Christiansen, Shelly Ann
    Swoboda, David
    Gardner, Kellie
    Rapisuwon, Suthee
    Atkins, Michael B.
    Gibney, Geoffrey Thomas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] Hepcidin expression as a predictive biomarker for anti-PD1/PDL1 antibody monotherapy for advanced non-small cell lung cancer
    Yamamoto, M.
    Kubo, S.
    Hirama, N.
    Teranishi, S.
    Tashiro, K.
    Seki, K.
    Maeda, C.
    Hiro, S.
    Kajita, Y.
    Sugimoto, C.
    Segawa, W.
    Nagayama, H.
    Nagaoka, S.
    Kudo, M.
    Kaneko, T.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1049 - S1050
  • [25] Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study
    Sun, Yiting
    Jiang, Liqing
    Wen, Ti
    Guo, Xiaoyu
    Shao, Xinye
    Qu, Hui
    Chen, Xi
    Song, Yujia
    Wang, Fang
    Qu, Xiujuan
    Li, Zhi
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [26] Analysis of response rate with anti-PD1/PDL1 antibodies in advanced solid tumors: A meta-analysis of randomized clinical trials (RCT).
    Carretero-Gonzalez, Alberto
    Lora, David
    Ghanem, Ismael
    Zugazagoitia, Jon
    Castellano, Daniel
    Sepulveda, Juan Manuel
    Lopez-Martin, Jose A.
    de Velasco, Guillermo
    Paz-Ares, Luis G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [27] Clinicogenomic predictors of extreme responses to anti-PD1/PDL1 checkpoint inhibitors (CPI) in metastatic urothelial cancer (mUC).
    Teo, Min Yuen
    Whiting, Karissa
    Mota, Jose Mauricio
    Li, Han
    Regazzi, Ashley Marie
    Solit, David B.
    Aggen, David Henry
    Lee, Chung-Han
    Funt, Samuel Aaron
    Bajorin, Dean F.
    Ostrovnaya, Irina
    Iyer, Gopa
    Rosenberg, Jonathan E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] Clinical Significance of PD1 and PDL1 in Human Breast Cancer
    Uhercik, Michal
    Sanders, Andrew J.
    Owen, Sioned
    Davies, Eleri L.
    Sharma, Anup K.
    Jiang, Wen G.
    Mokbel, Kefah
    [J]. ANTICANCER RESEARCH, 2017, 37 (08) : 4249 - 4254
  • [29] EFFICACY AND OUTCOME OF ANTI-PD1 THERAPY IN PATIENTS WITH LUNG CANCER BRAIN METASTASIS
    Thapa, Bicky
    Shah, Bhavan
    Lauko, Adam
    Ahluwalia, Manmeet
    [J]. NEURO-ONCOLOGY, 2017, 19 : 39 - 39
  • [30] A multicenter analysis of melanoma recurrence following adjuvant anti-PD1 therapy.
    Owen, Carina N.
    Larkin, James M. G.
    Shoushtari, Alexander Noor
    Carlino, Matteo S.
    Blank, Christian U.
    Lee, Belinda
    Mangana, Joanna
    Atkinson, Victoria
    Millward, Michael
    Zaman, Farzana
    Young, Arissa
    Khattak, Muhammad Adnan
    Patel, Sapna Pradyuman
    Hoeller, Christoph
    Hersey, Peter
    Chauhan, Dharmisha
    Palmieri, David James
    Lo, Serigne
    Menzies, Alexander M.
    Long, Georgina V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345